Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases
Here, we retrospectively review imaging of 68 consecutive unselected patients with BRAF V600‐mutant metastatic melanoma for organ‐specific response and progression on vemurafenib. Complete or partial responses were less often seen in the central nervous system (CNS) (36%) and bone (16%) compared to...
Main Authors: | Seifert, Heike, Hirata, Eishu, Gore, Martin, Khabra, Komel, Messiou, Christina, Larkin, James, Sahai, Erik |
---|---|
Format: | Online |
Language: | English |
Published: |
John Wiley and Sons Inc.
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737278/ |
Similar Items
-
Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling
by: Hirata, Eishu, et al.
Published: (2015) -
Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer
by: Nicoś, Marcin, et al.
Published: (2015) -
Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation
by: Fisher, Rosalie, et al.
Published: (2012) -
Pazopanib-Induced Alopecia, an Underestimated Toxicity?
by: Biondo, Andrea, et al.
Published: (2015) -
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
by: Fisher, Rosalie, et al.
Published: (2012)